ResearcherUniversity of MilanActive in the last 2 years
Vincenzo Mazzaferro
Matched on ORCID iD 0000-0002-4013-8085; OpenAlex author ID A5064470324. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 48
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers
Papers 9
- Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
- Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
- Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/his.70108↗
- Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. Last author DOI 10.1016/j.suronc.2025.102208↗
- NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1001/jamanetworkopen.2023.50756↗
- Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
- Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Co-author DOI 10.1002/cam4.70393↗
- REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
- Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giuseppe Leoncini · 3 shared papers, 2024–2026 · strength 0.69
- Paper Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma. DOI 10.1111/his.70108↗
- Paper Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma. DOI 10.1016/j.suronc.2025.102208↗
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393↗
- Federico Nichetti · 3 shared papers, 2024–2026 · strength 0.54
- Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
- Paper NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer:… DOI 10.1001/jamanetworkopen.2023.50756↗
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393↗
- Monica Niger · 3 shared papers, 2024–2026 · strength 0.54
- Paper Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter… DOI 10.1016/j.esmogo.2025.100276↗
- Paper NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer:… DOI 10.1001/jamanetworkopen.2023.50756↗
- Paper Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. DOI 10.1002/cam4.70393↗
- Sara Pusceddu · 2 shared papers, 2024 · strength 0.33
- Davide Citterio · 1 shared paper, 2025 · strength 0.23
- Andrea Zironda · 1 shared paper, 2025 · strength 0.23
- Michele Mazzola · 1 shared paper, 2025 · strength 0.23
- Giovanni Carlo Ferrari · 1 shared paper, 2025 · strength 0.23
- Samuele Grandi · 1 shared paper, 2025 · strength 0.23
- Mario Scartozzi · 1 shared paper, 2026 · strength 0.21
- Caterina Vivaldi · 1 shared paper, 2026 · strength 0.21
- Andrea Pretta · 1 shared paper, 2026 · strength 0.21
- Carolina Sciortino · 1 shared paper, 2026 · strength 0.21
- P. Andena · 1 shared paper, 2026 · strength 0.21
- Lisa Salvatore · 1 shared paper, 2026 · strength 0.21
- Giampaolo Tortora · 1 shared paper, 2026 · strength 0.21
- Alessandro Cucchetti · 1 shared paper, 2024 · strength 0.18
- Giuseppe Malleo · 1 shared paper, 2024 · strength 0.18
- Giulio Belfiori · 1 shared paper, 2024 · strength 0.18
- Fabio Casciani · 1 shared paper, 2024 · strength 0.18
- Riccardo Casadei · 1 shared paper, 2024 · strength 0.18
- Claudio Ricci · 1 shared paper, 2024 · strength 0.18
- Alessandro Ferrero · 1 shared paper, 2024 · strength 0.18
- Serena Langella · 1 shared paper, 2024 · strength 0.18
- Giorgio Ercolani · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.